Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...

Valo Health is eligible for a further $1.9 billion in potential milestone payments for up to nine new drug programs "Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact -- Update," at ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...

Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss drug ...

Hemophilia News Today compiled a summary of the 10 most read hemophilia stories of 2024, with links to the individual items.

A final decision is expected soon. Beyond diabetes and obesity, Novo Nordisk is diversifying its portfolio by developing Mim8 for hemophilia A, with plans to submit it for regulatory approval soon.

Shares of drugmaker Novo Nordisk (NVO) sold off sharply last week, falling as much as 29% intraday Friday (before closing down 17%) and wiping out nearly $100B of market value in the process when ...

Novo Nordisk blueprints $1.2B rare disease production ... To take on Roche’s blockbuster, Novo is advancing Mim8, a bispecific antibody designed to bridge Factor IXa and X to replace missing ...

Skuffende data for vægttabsmidlet Cagrisema sendte Novo Nordisk-aktien ned med 20,7 procent fredag Novo Nordisk-aktien styrdykkede med over 20 procent fredag efter offentliggørelsen af ...